Effect of amitriptyline on gastrointestinal function and brain-gut peptides: A double-blind trial

Table 3 Baseline and after treatment with placebo

Variable	Baseline (n = 28)	Placebo (n = 28)	P value
Cross-sectional area of the proximal stomach (cm2)
200 mL	17.95 ± 3.62	16.56 ± 3.98	0.19
400 mL	29.97 ± 6.35	27.84 ± 5.95	0.09
600 mL	40.78 ± 9.54	34.85 ± 6.61	0.06
800 mL	46.34 ± 9.67	40.86 ± 8.45	0.06
Difficulty in drinking water VAS
200 mL	0.93 ± 0.59	0.96 ± 0.56	0.70
400 mL	1.82 ± 0.54	1.82 ± 0.54	1.00
600 mL	3.36 ± 0.72	3.57 ± 0.94	0.34
800 mL	5.46 ± 0.73	5.57 ± 0.82	0.56
Gastric emptying
5 min	79.55 ± 6.35	78.84 ± 7.47	0.47
10 min	63.89 ± 8.39	64.54 ± 10.29	0.79
OCTT (min)	85.18 ± 19.60	96.61 ± 23.90	0.07
Plasma levels (pg/mL)
MTL	471.75 ± 127.02	473.40 ± 122.75	0.75
Ghrelin	452.50 ± 173.46	442.87 ± 176.79	0.35
NPY	901.17 ± 144.91	890.15 ± 131.46	0.12

Values are represented as mean ± SD. Symptom scores on 10-cm visual analogue scale. OCTT: Orocecal transit time; MTL: Motilin; NPY: Neuropeptide Y; VAS: Visual analogue scale.